CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension

Abstract excerpt

BACKGROUND: Patients with pulmonary arterial hypertension (PAH) carrying bone morphogenetic protein receptor type 2 (Bmpr2) mutations present earlier with severe hemodynamic compromise and have poorer survival outcomes than those without mutation. The mechanism underlying the worsening clinical phenotype of PAH with Bmpr2 mutations has been largely unaddressed in rat models of pulmonary hypertension (PH) because...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cardiac Valve Diseases and Treatments
• Share to Phosphodiesterase function and regulation
• Share to Pulmonary Hypertension Research and Treatments